PATENTS *lfw*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kurukulasuriya et al.

Serial No.: 10/743,954

Filed: December 23, 2003

Title: GLUCAGON RECEPTOR
ANTAGONISTS/INVERSE AGONISTS

Case No.: 7023US02

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: June 17, 2004

Tanya Parent

Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTS are the following:


1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. References as cited on PTO 1449 (54 references); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,
Kurukulasuriya et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623

Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kurukulasuriya et al.

Serial No.: 10/743,954

Filed: December 23, 2003

Title: GLUCAGON RECEPTOR
ANTAGONISTS/INVERSE AGONISTS

Case No.: 7023US02

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: June 17, 2004

Tanya Parent 6/17/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,
Kurukulasuriya et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623


Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants



DATE: June 17, 2004 SHEET 1 of 2

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

7023US02

SERIAL NO.

10/743,954

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

R. Kurukulasuriya et al.

FILING DATE

December 23, 2003

GROUP

1614

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	A1	5	7	7	6	9	5	4	07/07/98	de Laszlo, et al.			
	A2	5	8	8	0	1	3	9	03/09/99	Chang			
	A3	6	2	1	8	4	3	1	04/17/2001	Schoen, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER							PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
													YES	NO
	B1	9	7	1	6	4	4	2	09.05.97	WO				
	B2	9	8	2	1	9	5	7	28.05.98	WO				
	B3	9	8	2	2	1	0	8	28.05.98	WO				
	B4	9	8	2	2	1	0	9	28.05.98	WO				
	B5	9	9	0	1	4	2	3	14.01.99	WO				
	B6	0	0	3	9	0	8	8	06.07.2000	WO				
	B7	0	0	6	9	8	1	0	23.11.2000	WO				
	B8	0	2	0	0	6	1	2	03.01.2002	WO				
	B9	0	2	4	0	4	4	4	23.05.2002	WO				
	B10	0	2	4	0	4	4	5	23.05.2002	WO				
	B11	0	2	4	0	4	4	6	23.05.2002	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Ahrén, B., & Larsson, H., "Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations", <i>Diabetologia</i> , 44 :1998-2003 (2001)
C2	Baron, A. C., et al., "Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics", <i>Diabetes</i> , 36 :274-283 (1987)
C3	Brand, C. L., et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose In Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits", <i>Diabetes</i> , 46 :1076-1083 (1996)
C4	Brand, C. L., et al., "Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats", <i>Diabetologia</i> , 37 :985-993 (1994)
C5	Brand, C. L., et al., <i>American Diabetes Assn Poster Session in San Antonio, TX</i> , pgs. A81 & A428 (2000)
C6	Cascieri, M. A., et al., "Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor", <i>The Journ. of Biol. Chem.</i> 1999 , 274 :8694-8697 (1999)
C7	Chang, L. L., et al., "Substituted Imidazoles as Glucagon Receptor Antagonists", <i>Bioorganic & Med. Chem. Ltrs.</i> , 11 :2549-2553 (2001)
C8	de Feo, P., et al., "Contribution of cortisol to glucose counterregulation in humans", <i>Am. J. Physiol.</i> 257 :E35-E42 (1989)
C9	de Laszlo, S. E., et al., "POTENT, ORALLY ABSORBED GLUCAGON RECEPTOR ANTAGONISTS", <i>Bioorganic & Med. Chem. Ltrs.</i> , 9 :641-646
C10	DeFronzo, R. A., "Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes", <i>Diabetes Reviews</i> , 5 (3):177-269 (1997)

C11	Dinneen, S., <i>et al.</i> , "Metabolic Effects of the Nocturnal Rise in Cortisol on Carbohydrate Metabolism in Normal Humans", <i>J. Clin. Invest.</i> 92 :2283-2290 (1993)
C12	Dobbs, R., <i>et al.</i> , "Glucagon: Role in the Hyperglycemia of Diabetes Mellitus", <i>Science</i> , 187 :544-547 (1975)
C13	Friedman <i>et al.</i> , <i>J. Biol. Chem.</i> , 272 (50):31475-31481 (1997)
C14	Guillon, J., <i>et al.</i> , "Synthesis of new pyrrolo[1,2- α]quinoxalines: potential non-peptide glucagon receptor antagonists", <i>Eur. J. Med. Chem.</i> , 33 :293-308 (1998)
C15	Ladouceur, G. H., <i>et al.</i> , "4-Phenylpyridine glucagon receptor antagonists: synthetic approaches to the sterically hindered chiral hydroxy group", <i>Tetrahedron Lett.</i> , 43 :4455-4458 (2002)
C16	Ladouceur, G. H., <i>et al.</i> , "Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists", <i>Bioorganic & Med. Chem. Lett.</i> , 12 :461-464 (2002)
C17	Langley <i>et al.</i> , <i>Am. J. Physiol.</i> 259 (Regulatory Integrative Comp. Physiol. 28):R539-R544 (1990)
C18	Ling, A., <i>et al.</i> , "Human Glucagon Receptor Antagonists Based on Alkylidene Hydrazides", <i>Bioorganic & Med. Chem. Lett.</i> , 12 :663-666 (2002)
C19	Ling, A., <i>et al.</i> , "Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 44 :3141-3149 (2001)
C20	Madsen, P., <i>et al.</i> , "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 41 :5150-5157 (1998)
C21	Magnusson, I., <i>et al.</i> , "Increased Rate of Gluconeogenesis in Type II Diabetes Mellitus A ¹³ C Nuclear Magnetic Resonance Study", <i>J. Clin. Invest.</i> , 90 :1323-1327 (1992)
C22	Parker, J. C., <i>et al.</i> , "Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and Human Hepatocytes", <i>Diabetes</i> , 49 :2079-2086 (2000)
C23	Petersen K. F. & Sullivan, J. T., "Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans", <i>Diabetologia</i> , 44 :2018-2024
C24	Post, S. R., <i>et al.</i> , "Mechanism of Action of des-His ¹ [Glu ⁹]glucagon amide, a peptide antagonist of the glucagon receptor system", <i>Proc. Natl. Acad. Sci. USA</i> , 90 :1662-1666 (1993)
C25	Reaven, G. M., <i>et al.</i> , "Documentation of Hyperglucagonemia Throughout the Day in Nonobese and Obese Patients with Noninsulin-Dependent Diabetes Mellitus", <i>J. of Clin. Endocrin. & Metab.</i> , 64 :106-110 (1987)
C26	Rizza, R., <i>et al.</i> , "Effect of Intermittent Endogenous Hyperglucagonemia on Glucose Homeostasis in Normal and Diabetic Man", <i>J. Clin. Invest.</i> , 63 :1119-1123 (1979)
C27	Rooney, D. P., <i>et al.</i> , "The Effect of Cortisol on Glucose/Glucose-6-Phosphate Cycle Activity and Insulin Action", <i>J. Clin. Endocrin. & Metabol.</i> , 77 :1180-1183 (1994)
C28	Shah, P., <i>et al.</i> , "Impact of lack of suppression of glucagon on glucose tolerance in humans", <i>Am. J. Physiol.</i> , 277 :E283-E290 (1999)
C29	Shah, P., <i>et al.</i> , "Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus", <i>J. Clin. Endocrinol. & Metabol.</i> , 85 :4053-4059 (2000)
C30	Smith, R. A., "Optimization of the 4-Aryl Group of 4-Aryl-pyridine Glucagon Antagonists: Development of an Efficient, Alternative Synthesis", <i>Bioorganic & Medicinal Chem. Lett.</i> , 12 :1303-1306 (2002)
C31	Terleckyj, I., <i>et al.</i> , "The Glucagon Receptor Antagonist ALT 3000 Lowers Fasting Hyperglycemia in Rat Models of Diabetes", <i>Diabetes</i> , 45 :220A (1996)
C32	Unger, R. H., & Orci, L., "Glucagon", <i>Joslin's Diabetes Mellitus</i> , Chapt. 9 :163-176 (1994)
C33	Unger, R. H., "Glucagon physiology and pathophysiology in the light of new advances", <i>Diabetologia</i> , 28 :574-578 (1985)
C34	Unger, R. H., "Role of Glucagon in the Pathogenesis of Diabetes: The Status of the Controversy", <i>Metabolism</i> , 27 (11):1691-1709 (1978)
C35	Unger, R. H., "THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS", <i>Lancet</i> , 1 :14-16 (1975)
C36	Unson, C. G., <i>et al.</i> , "Biological Activities of des-His ¹ [Glu ⁹]Glucagon Amide, a Glucagon Antagonist ¹ ", <i>Peptides</i> , 10 :1171-1177 (1989)
C37	Unson, C. G., <i>et al.</i> , "Multiple-site Replacement Analogs of Glucagon", <i>Journ. of Biol. Chem.</i> , 269 (17):12548-12551 (1994)
C38	Walker <i>et al.</i> , <i>Am. J. Physiol.</i> 262 (Endocrinol. Metab. 25):E110-E117 (1992)
C39	Wright, L. M., <i>et al.</i> , "Structure of Fab hGR-2 F6, a competitive antagonist of the glucagon receptor", <i>Acta Cryst.</i> , D56 :573-580 (2000)
C40	Ziezech, B. Y., <i>et al.</i> , "[des His ¹ , des Phe ⁶ , Glu ⁹]GLUCAGON AMIDE: A NEWLY DESIGNED "PURE" GLUCAGON ANTAGONIST", <i>Bioorganic & Medic. Chem. Lett.</i> , 5 (16):1849-1852 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)